Anaplastic Lymphoma Kinase Inhibitors Market

The anaplastic lymphoma kinase (ALK) gene is a member of the insulin receptor superfamily and it has been linked with more than twenty distinct chimera that include established drivers of several human cancers. Non-small-cell lung carcinoma (NSCLC) is highly likely to metastasize into the bones and other tissues, making it difficult to detect and treat. NSCLC accounts for 90% of all lung cancer cases. The market is witnessing strong growth due to high awareness among the population through government initiatives. Furthermore, the drugs for NSCLC are given swift approvals by regulatory bodies and fundings for research. This has led to a new generation of drugs being introduced in the NSCLC market. The major classes of drugs under NSCLC are angiogenesis inhibitor, EGFR blocker, anaplastic lymphoma kinase inhibitor, microtubule stabilizer, folate antimetabolites, and PD-1/PD-L1 inhibitors. 

Global Anaplastic Lymphoma Kinase Inhibitors Market: Dynamics 

Growth of Bio-pharmaceutical Industries and Increasing Strategic Collaborations Boosting Market 

Increase in number of strategic collaborations between manufacturers and research institutes along with rapidly growing health care and pharmaceutical industries in developed and developing economies are some factors that are anticipated to assist the global anaplastic lymphoma kinase inhibitors market during the forecast period. 

In 2017, Novartis AG entered into strategic agreement with Wyss Institute at Harvard University and the Dana-Farber Cancer Institute to develop biomaterial systems for immuno-oncology therapies. 

Increase in Health Care Expenditure Boosting Market 

Emerging economics such as India, China, Brazil, Malaysia, and other emerging countries in developing regions such as Asia Pacific, Middle East & Africa, and Latin America offer numerous opportunities in health care sector. Increased government expenditure in health care segment is likely to pace up the expansion of anaplastic lymphoma kinase inhibitors market during the forecast period. For instance, according to the Union Budget 2017-18, in India, the total health care expenditure was increased from 1.97% to 2.27% of total Union Budget. 

Increasing Prevalence of NSCLC 

Increase in number of patients throughout the world in developing as well as developed economies is anticipated to increase the demand for therapeutics and is expected to drive the global anaplastic lymphoma kinase inhibitors market during the forecast period. For instance, in 2018, approximately 2.1 million new cases of lung cancer were diagnosed across the globe. Lung cancer records the highest mortality rate among developing countries compared to all type of cancers, with developed regions such as North America and Europe ensuring the highest rates. 

Global Anaplastic Lymphoma Kinase Inhibitors Market: Competitive Landscape 

Major players operating in the global anaplastic lymphoma kinase inhibitors market include F. Hoffman-La Roche Ltd., Helsinn Therapeutics, Novartis AG, Oncoethix GmbH, Pfizer, Inc., and Takeda Pharmaceutical Co., Ltd. 

Hoffman-La Roche Ltd. 

Hoffmann-La Roche Ltd. (Roche) is a leading global health care and biotech company that engages in development and marketing of pharmaceuticals, biopharmaceuticals, and In Vitro Diagnostic (IVD) devices & consumables. The company operates through two divisions: Pharmaceuticals and Diagnostics. Its pharmaceuticals business segment provides therapies in the field of oncology, immunology, neuroscience, ophthalmology, infectious diseases, and others. Roche, which also offers diagnostic solutions for oncology and other chronic diseases, has built an expertise in cancer biomarker identification and biological drugs. This has boosted the company’s oncology portfolio. 

Pfizer, Inc. 

Pfizer Inc. is a leading biopharmaceutical company that is focused on discovery, development, manufacturing, and commercialization of health care products. Its portfolio includes consumer health care products, vaccines, and medicines. Pfizer operates through two key business segments: Pfizer Essential Health (EH) and Pfizer Innovative Health (IH). Under the Innovative Health segment, the company offers branded oncology and other therapy drugs, while it offers biosimilars for oncology and other indications under the Essential Health segment. Pfizer offers oncology drugs across therapy lines, such as antibody drug conjugate, monoclonal antibodies, and kinase inhibitors. 

Global Anaplastic Lymphoma Kinase Inhibitors Market: Segmentation 

The global anaplastic lymphoma kinase inhibitors market can be segmented based on:

• Type
• Region 

In terms of type, the anaplastic lymphoma kinase inhibitors market can be classified into: 

• Second-generation ALK inhibitors
• First-generation ALK inhibitors
• Third-generation ALK inhibitors 

In terms of region, the global anaplastic lymphoma kinase inhibitors market can be segmented into:

• North America
• Latin America
• Europe
• Asia Pacific
• Middle East & Africa (MEA) 

North America accounted for the dominant share of the global anaplastic lymphoma kinase inhibitors market in 2018 owing to the presence of modern health care infrastructure and an efficient U.S. government system. However, Asia Pacific is expected to expand at the highest CAGR during the forecast period. Factors such as increasing population, greater awareness about NSCLC, and increasing number of government projects related to lung, cancer and their respective interventions would boost the market in APAC during the forecast period.